Case Presentations and Panel Discussion (Elderly AML, Slow Responding or Emerging Mutation CML, “Incidental” Identification of a JAK2 Mutant Clone)
This information was originally presented at the NCCN 11th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Describe the clinical challenges in managing patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.
- Develop an evidence-based approach for the management of patients with elderly AML, slow responding or emerging mutation CML and “incidental” identification of a JAK2 mutant clone.
Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Ruben A. Mesa, MD
Mayo Clinic Cancer Center
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The faculty listed below have disclosed the following relevant financial relationships:
Jessica K. Altman, MD
Astellas Pharma US, Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Fujifilm Corporation: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Ruben A. Mesa, MD
ARIAD Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Grant/Research Support
CTI BioPharma Corp.: Grant/Research Support
Galena Biopharma, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria
Promedior, Inc.: Grant/Research Support
Jerald P. Radich, MD
ARIAD Pharmaceuticals, Inc.: Scientific Advisor
Incyte Corporation: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Anne Bergman; Hema Sundar, PhD
The NCCN clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:
Courtney Smith, PhD
Johnson & Johnson: Equity Interest/Stock Options
Opko Health Inc: Equity Interest/Stock Options
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim onlhy the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.92 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-114-H01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 0.92 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing